Rod Balhorn

TL;DR: The alkylation of histones by the direct-acting carcinogen 7-bromomethylbenz[a]anthracene was demonstrated both in vivo and in vitro and three major adducts were observed and tentatively identified as cysteinyl, lysyl and histidinylAdducts of histone H3.

TL;DR: Balhorn et al. as discussed by the authors proposed SH7139, a new class of cancer therapeutics developed for treating non-Hodgkin’s lymphoma, is unusual in that both targeting and pro-drug functionalities have been incorporated into the same small molecule.

TL;DR: The conformation of the non-glycosylated recombinant form of the extracellar domain of rat MOG (rMOG(1-125)) dissolved in different solvent conditions was studied by CD spectroscopy and shows that this 'beta-form' is stabilized by zwitterionic phospholipids, DPC and LPCP.

TL;DR: selective High Affinity Ligands, the first SHAL therapeutic for treating advanced non-Hodgkin’s lymphoma, has shown remarkable efficacy in B-cell lymphoma xenograft models by providing permanent cures for up to two-thirds of the animals at a human equivalent dose as low as 0.4 μg/kg.

TL;DR: A recombinant form of the beta subunit of HLA-DR10 in Escherichia coli can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.